Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Apr 26, 2025; 17(4): 103919
Published online Apr 26, 2025. doi: 10.4252/wjsc.v17.i4.103919
Published online Apr 26, 2025. doi: 10.4252/wjsc.v17.i4.103919
Human umbilical cord mesenchymal stem cell-derived exosomal miR-199a-3p inhibits the MAPK4/NF-κB signaling pathway to relieve osteoarthritis
Ling-Qiang Chen, Department of Orthopedics, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan Province, China
Sha Ma, Juan Yu, Da-Chen Zuo, Zi-Jing Yin, Fa-You Li, Xia He, Hai-Ting Peng, Xiao-Qing Shi, Wei-Juan Huang, Qin Li, Jing Wang, Department of Rheumatology, The First People’s Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming 650032, Yunnan Province, China
Author contributions: Chen LQ and Wang J contributed to the project administration and resources; Chen LQ and Ma S contributed to the validation; Chen LQ and Yu J contributed to the visualization of this manuscript; Chen LQ contributed to conceptualization and writing original draft of the manuscript; Ma S and Yu J contributed to data curation; Zuo DC and Yin ZJ contributed to formal analysis; Wang J contributed to funding acquisition, investigation, and writing review and editing; Li FY and He X contributed to methodology; Peng HT and Shi XQ contributed to software; Huang WJ and Li Q contributed to supervision of this manuscript. All authors have read and approved the final manuscript.
Supported by Basic Research Plan of Yunnan Province, No. 202201AT070059; National Natural Science Foundation of China, No. 81760407; Science and Technology Talent and Platform Plan of Yunnan Provincial Department of Science and Technology, No. 202205AC160066.
Institutional animal care and use committee statement: All procedures involving animals are reviewed and approved by the Experimental Animal Ethics Committee of Kunming University of Science and Technology.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Data sharing statement: No additional data are available.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jing Wang, Department of Rheumatology, The First People’s Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, No. 157 Jinbi Road, Xishan District, Kunming 650032, Yunnan Province, China.
Received: December 16, 2024
Revised: January 25, 2025
Accepted: March 13, 2025
Published online: April 26, 2025
Processing time: 130 Days and 21.3 Hours
Revised: January 25, 2025
Accepted: March 13, 2025
Published online: April 26, 2025
Processing time: 130 Days and 21.3 Hours
Core Tip
Core Tip: Osteoarthritis (OA), a debilitating joint disorder, currently lacks effective treatment options. This study reveals that exosomal miR-199a-3p derived from human umbilical cord mesenchymal stem cells offers a novel therapeutic strategy for OA. By targeting the mitogen-activated protein kinase 4/nuclear factor-kappaB signaling pathway, miR-199a-3p significantly reduces inflammation and inhibits apoptosis in chondrocytes. These findings highlight the potential of exosomal miR-199a-3p delivery as a promising approach for managing OA, providing a foundation for future clinical applications.